Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Approval of biosimilar products can increase patient access to safe and effective treatment options. The FDA granted approval of Merilog to Sanofi-Aventis U.S. LLC. “The FDA has now approved three ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 ...

The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli. Sanofi recorded a $250 ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The ...

In ulcerative colitis, duvakitug led to clinical remission in up to 48% of patients, with placebo-adjusted rates of 27% at the highest dose. In Crohn's disease, duvakitug achieved endoscopic ...